I-UPDATE ang Hematology / Oncology 2024
ESMO Congress 2023
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Gumagamit ka ng mas lumang bersyon ng iyong web browser, kaya maaaring hindi maipakita nang maayos ang ilang feature.
MINIMAL na Kinakailangan: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
Nag-aalok na ngayon ang OncologyPRO ng mga mapagkukunan ng pagpupulong: +3.000 slide at webcast; abstract at ePoster.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Ang Daily Reporter177Lu PSMA-617 ay nagpapabuti ng rPFS para sa metastatic castration resistant na mga pasyente ng prostate cancer na taxane-naive23 Okt 2023Ang mga natuklasan ng PSMAfore trial ay limitado sa katotohanang hindi sila nagpapakita ng benepisyo sa mga tuntunin ng OS.
Magrehistro para sa mga tiket o booth
Mapa ng Lugar at Mga Hotel sa Paligid
Munich - Holiday Inn Munich - City Center, Bavaria, Germany Munich - Holiday Inn Munich - City Center, Bavaria, Germany
sumuskribi